On Friday, Pharmaceutical company Lupin said that it has partnered with Unitaid, the Aurum Institute, the Clinton Health Access Initiative (CHAI) and other global procurement agencies to support the TB Preventive Treatment Initiative rollout to 138 countries.

Under the agreement, the Mumbai-based company will launch two new formulations, a fixed-dose combination of rifapentine + isoniazid and a 300 mg stand-alone tablet of rifapentine, at affordable prices, including among many Tuberculosis (TB) burden in low-income countries.

As a global leader in anti-TB medicines, Lupin is committed to ensuring that its products are widely available globally and equitable access to treatment globally.

Lupin is an innovation-led multinational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a broad range of branded and generic formulations, biotech products and API East in over 100 markets in the United States, India, South Africa and Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East.